---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-045569"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:51:14.580512+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BriaCell reports prelim OS up to 2x literature in ADC-refractory breast cancer subset

## Summary
- 23 heavily pre-treated (median 6 prior therapies) advanced breast cancer patients, all failed ADCs (KADCYLA, ENHERTU, TRODELVY).
- Median OS up to twice that reported in comparable studies; 17 of 23 patients remain alive.
- Disease control rate of 40% in evaluable patients; PFS similar or better than last regimen in 40%.
- No toxicity-related discontinuations and no cases of Interstitial Lung Disease (ILD) with Bria-IMT regimen.

## SEC filing metadata
- accession: 0001493152-23-045569
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315223045569/0001493152-23-045569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315223045569/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-045569
- JSON: https://secwatch.observer/filing/0001493152-23-045569.json
- Plain text: https://secwatch.observer/filing/0001493152-23-045569.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.